drugset / Trial / NCT04480736
A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants
RandomizedParallel-groupDouble-blindOther
Summary
The purpose of this study is to assess the antiviral activity of JNJ-64281802 versus placebo in terms of reduction of dengue virus 1 (DENV-1) ribonucleic acid (RNA) viral load (VL).
Timeline
- Start
- 2020-07-28
- Primary completion
- 2027-09-02
- Completion
- 2027-12-09
Outcome
Outcome not reported
Stopped (Business): “portfolio reprioritization”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mosnodenvir | Small molecule | — | Oral |
Indications
No indication recorded.